Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain tumor drug delivered via pump shows promise in early trial

NCT ID NCT06666712

Recruiting now Disease control Sponsor: Jeffrey N. Bruce Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests the safety of delivering the chemotherapy drug topotecan directly to the brain using a pump and catheter system (convection-enhanced delivery) in 6 people with a recurrent, aggressive type of brain tumor called IDH-mutant malignant glioma. The treatment involves four infusions over about a month, followed by tumor removal. The goal is to see if this direct delivery method is safe and can help control the tumor.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN TUMOR RECURRENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

astrocytoma, IDH-mutant, grade 3 brain cancer brain neoplasm follicular lymphoma glioma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN TUMOR RECURRENT IDH1/IDH2 MUTATION MALIGNANT GLIOMA (WHO GRADE III OR IV)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Columbia University Irving Medical Center / NewYork-Presbyterian Hospital

    RECRUITING

    New York, New York, 10032, United States

    Contact

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.